What is MRD?
MRD is one of the strongest predictors of outcomes in blood cancers
Minimal residual disease (MRD) refers to the small number of cancer cells that can stay in the body during and after treatment. Often, these cells are present at such low levels that they do not cause any physical signs or symptoms. They may be a sign that cancer is returning.[1,2]
Today, new treatments are helping patients like you live longer than ever before. Some patients may have such low levels of remaining cancer cells that not all tests can detect them. Therefore, your doctor needs highly sensitive options, like the clonoSEQ test, to help measure MRD and assess therapy responses over time. [1-5]
As one of the strongest predictors of outcomes in blood cancers, MRD status can help you and your doctor understand your prognosis and how it may change over time.
When your MRD status shifts, you may find that the course of your blood cancer journey changes as well.
This page is intended for a US-based audience.
clonoSEQ® is an FDA-cleared test used to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). IGHV testing is also available as a CLIA-validated LDT. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.
clonoSEQ is only available by prescription from a licensed healthcare professional. Results may vary. Talk to your healthcare provider to see if clonoSEQ testing is right for you. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.
- clonoSEQ®. [technical summary]. Seattle, WA. Adaptive Biotechnologies; 2020. https://clonoseq.com/technical-summary.
- Pulsipher M, et al. Blood. 2015;125(22):3501-3508.
- Wood B, et al. Blood. 2018;131(12):1350-1359.
- Perrot A, et al. Blood. 2018;132(23):2456-2464.
- Thompson P, et al. Blood. 2019;134(22):1951-1959.